The molecular biology of head and neck cancer

Nature Reviews Cancer

Volumn 11, Issue 1, 2011, Pages 9-22

  Leemans, C René ^a   Braakhuis, Boudewijn J M ^a   Brakenhoff, Ruud H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P53;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURGERY; GENETIC HETEROGENEITY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 6; METASTASIS; NONHUMAN; PAPILLOMAVIRUS INFECTION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA;

ANIMALS; HEAD AND NECK NEOPLASMS; HUMANS; MOLECULAR BIOLOGY;

EID: 78650626081     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2982     Document Type: Review

References (154)

1. Kamangar, F., Dores, G. M. & Anderson, W. F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 24, 2137-2150 (2006).
2. Kutler, D. I. et al. High incidence of head and neck squamous cell carcinoma in patients with fanconi anemia. Arch. Otolaryngol. Head Neck Surg. 129, 106-112 (2003).
3. Hopkins, J. et al. Genetic polymorphisms and head and neck cancer outcomes: a review. Cancer Epidemiol. Biomark. Prev. 17, 490-499 (2008).
4. Cloos, J. et al. Genetic susceptibility to head and neck squamous cell carcinoma. J. Natl Cancer Inst. 88, 530-535 (1996).
5. Ang, K. K. et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 363, 24-35 (2010).
6. Smith, R. B., Sniezek, J. C., Weed, D. T. & Wax, M. K. Utilization of free tissue transfer in head and neck surgery. Otolaryngol. Head Neck Surg. 137, 182-191 (2007).
7. Vergeer, M. R. et al. Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program. Int. J. Radiat. Oncol. Biol. Phys. 74, 1-8 (2009).
8. Boscolo-Rizzo, P., Maronato, F., Marchiori, C., Gava, A. & Da Mosto, M. C. Long-term quality of life after total laryngectomy and postoperative radiotherapy versus concurrent chemoradiotherapy for laryngeal preservation. Laryngoscope 11 8, 300-306 (2008).
9. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
10. Woolgar, J. A. & Triantafyllou, A. Pitfalls and procedures in the histopathological diagnosis of oral and oropharyngeal squamous cell carcinoma and a review of the role of pathology in prognosis. Oral Oncol. 45, 361-385 (2009).
11. Chung, C. H. et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 5, 489-500 (2004).
12. Chung, C. H. et al. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kB signalling as characteristic of a high risk squamous cell carcinoma. Cancer Res. 66, 8210-8218 (2006).
13. Hermsen, M. et al. New chromosomal regions with high-level amplifications in squamous cell carcinomas of the larynx and pharynx, identified by comparative genomic hybridization. J. Pathol. 194, 177-182 (2001).
14. Jin, C. et al. Cytogenetic abnormalities in 106 oral squamous cell carcinomas. Cancer Genet. Cytogenet. 164, 44-53 (2006).
15. Smeets, S. J. et al. Genetic classification of oral and oropharyngeal carcinomas identifies subgroups with a different prognosis. Cell. Oncol. 31, 291-300 (2009).
16. Walboomers, J. M. et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189, 12-19 (1999).
17. Zur Hausen, H. Papillomaviruses and cancer: from basic studies to clinical application. Nature Rev. Cancer 2, 342-350 (2002).
18. Munoz, N. et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348, 518-527 (2003). (Pubitemid 36159887)
19. Syrjanen, S. Human papillomavirus (HPV) in head and neck cancer. J. Clin. Virol. 32, S59-S66 (2005).
20. Snijders, P. J. F. et al. Prevalence and expression of human papillomavirus in tonsillar carcinomas, indicating a possible viral etiology. Int. J. Cancer 51, 845-850 (1992).
21. Gillison, M. L. et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J. Natl Cancer Inst. 92, 709-720 (2000).
22. Meijer, C. J. et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int. J. Cancer 124, 516-520 (2009).
23. Snijders, P. J., van den Brule, A. J. & Meijer, C. J. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J. Pathol. 201, 1-6 (2003).
24. Van Houten, V. M. M. et al. Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. Int. J. Cancer 93, 232-235 (2001).
25. Wiest, T., Schwarz, E., Enders, C., Flechtenmacher, C. & Bosch, F. X. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 21, 1510-1517 (2002).
26. Braakhuis, B. J. M. et al. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J. Natl Cancer Inst. 96, 998-1006 (2004).
27. Smeets, S. J. et al. Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene 25, 2558-2564 (2006).
28. Slebos, R. J. C. et al. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin. Cancer Res. 12, 701-709 (2006).
29. Smeets, S. J. et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int. J. Cancer 121, 2465-2472 (2007).
30. Robinson, M., Sloan, P. & Shaw, R. Refining the diagnosis of oropharyngeal squamous cell carcinoma using human papillomavirus testing. Oral Oncol. 46, 492-496 (2010).
31. D'Souza, G. et al. Case-control study of human papillomavirus and oropharyngeal cancer. N. Engl. J. Med. 356, 1944-1956 (2007).
32. Ragin, C. C. R. & Taioli, E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int. J. Cancer 121, 1813-1820 (2007).
33. Poeta, M. L. et al. Tp53 mutations and survival in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 357, 2552-2561 (2007).
34. Westra, W. H. et al. Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin. Cancer Res. 14, 366-369 (2008).
35. Napier, S. S. & Speight, P. M. Natural history of potentially malignant oral lesions and conditions: an overview of the literature. J. Oral Pathol. Med. 37, 1-10 (2008).
36. Van Der Waal, I. Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. Oral Oncol. 45, 317-323 (2009).
37. Lodi, G., Sardella, A., Bez, C., Demarosi, F. & Carrassi, A. Interventions for treating oral leukoplakia. Cochrane Database Syst. Rev. CD001829 (2006).
38. Partridge, M. et al. A case-control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma within a field of cancerization. Cancer Res. 60, 3893-3898 (2000).
39. Wrangle, J. M. & Khuri, F. R. Chemoprevention of squamous cell carcinoma of the head and neck. Curr. Opinion Oncol. 19, 180-187 (2007).
40. Schaaij-Visser, T. B. M. et al. Evaluation of cornulin, keratin 4, keratin 13 expression and grade of dysplasia for predicting malignant progression of oral leukoplakia. Oral Oncol. 46, 123-127 (2010).
41. Rosin, M. P. et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin. Cancer Res. 6, 357-362 (2000).
42. Mao, L. et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nature Med. 2, 682-685 (1996).
43. Torres-Rendon, A., Stewart, R., Craig, G. T., Wells, M. & Speight, P. M. DNA ploidy analysis by image cytometry helps to identify oral epithelial dysplasias with a high risk of malignant progression. Oral Oncol. 45, 468-473 (2009).
44. Shpitzer, T. et al. Salivary analysis of oral cancer biomarkers. Brit. J. Cancer 101, 1194-1198 (2009).
45. Bremmer, J. F. et al. A noninvasive genetic screening test to detect oral preneoplastic lesions. Lab. Invest. 85, 1481-1488 (2005).
46. Bremmer, J. F. et al. Screening for oral precancer with noninvasive genetic cytology. Cancer Prev. Res. 2, 128-133 (2009).
47. Slaughter, D. P., Southwick, H. W. & Smejkal, W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 6, 963-968 (1953).
48. Califano, J. et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res. 56, 2488-2492 (1996).
49. Tabor, M. P. et al. Persistence of genetically altered fields in head and neck cancer patients: Biological and clinical implications. Clin. Cancer Res. 7, 1523-1532 (2001).
50. Tabor, M. P. et al. Comparative molecular and histological grading of epithelial dysplasia of the oral cavity and the oropharynx. J. Pathol. 199, 354-360 (2003).
51. Willis, R. A. The mode of origin of tumors. Solitary localized squamous cell growths of the skin. Cancer Res. 4, 469-479 (1944).
52. Slaughter, D. P. Multicentric origin of intraoral carcinoma. Surgery 133-146 (1946).
53. Hittelman, W. N. Genetic instability in epithelial tissues at risk for cancer. Ann. NY Acad. Sci. 952, 1-12 (2001).
54. Tabor, M. P. et al. Genetically altered fields as origin of locally recurrent head and neck cancer: a retrospective study. Clin. Cancer Res. 10, 3607-3613 (2004).
55. Roesch-Ely, M. et al. Proteomic analysis reveals successive aberrations in protein expression from healthy mucosa to invasive head and neck cancer. Oncogene 26, 54-64 (2007).
56. Schaaij-Visser, T. B. M. et al. Differential proteomics identifies protein biomarkers that predict local relapse of head and neck squamous cell carcinomas. Clin. Cancer Res. 15, 7666-7675 (2009).
57. Braakhuis, B. J. M., Tabor, M. P., Kummer, J. A., Leemans, C. R. & Brakenhoff, R. H. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res. 63, 1727-1730 (2003).
58. Van Houten, V. M. et al. Mutated p53 as a molecular marker for the diagnosis of head and neck cancer. J. Pathol. 198, 476-486 (2002).
59. Jonason, A. S. et al. Frequent clones of p53-mutated keratinocytes in normal human skin. Proc. Natl Acad. Sci. USA 93, 14025-14029 (1996).
60. Dakubo, G. D., Jakupciak, J. P., Birch-Machin, M. A. & Parr, R. L. Clinical implications and utility of field cancerization. Cancer Cell. Int. 7, 2 (2007).
61. Negrini, S., Gorgoulis, V. G. & Halazonetis, T. D. Genomic instability - an evolving hallmark of cancer. Nature Rev. Mol. Cell Biol. 11, 220-228 (2010).
62. Patmore, H. S., Cawkwell, L., Stafford, N. D. & Greenman, J. Unraveling the chromosomal aberrations of head and neck squamous cell carcinoma: a review. Ann. Surg. Oncol. 12, 831-842 (2005).
63. Wreesmann, V. B. & Singh, B. Chromosomal aberrations in squamous cell carcinomas of the upper aerodigestive tract: biologic insights and clinical opportunities. J. Oral Pathol. Med. 34, 449-459 (2005).
64. Ha, P. K., Chang, S. S., Glazer, C. A., Califano, J. A. & Sidransky, D. Molecular techniques and genetic alterations in head and neck cancer. Oral Oncol. 45, 335-339 (2009).
65. Carbone, M., Klein, G., Gruber, J. & Wong, M. Modern criteria to establish human cancer etiology. Cancer Res. 64, 5518-5524 (2004). (Pubitemid 39006577)
66. Kastan, M. B. & Bartek, J. Cell-cycle checkpoints and cancer. Nature 432, 316-323 (2004).
67. Balz, V. et al. Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res. 63, 1188-1191 (2003).
68. Opitz, O. G. et al. Cyclin D1 overexpression and p53 inactivation immortalize primary oral keratinocytes by a telomerase-independent mechanism. J. Clin. Invest. 108, 725-732 (2001).
69. INK4A- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Mol. Cell. Biol. 22, 5157-5172 (2002).
70. Smeets, S. J. et al. Immortalization of oral keratinocytes by functional inactivation of the p53 and pRb pathways. Int. J. Cancer (in the press).
71. Reed, A. L. et al. High frequency of p16 (CDKN2/ MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res. 56, 3630-3633 (1996).
72. Gibcus, J. H. et al. Amplicon mapping and expression profiling identify the Fas-associated death domain gene as a new driver in the 11q13.3 amplicon in laryngeal/pharyngeal cancer. Clin. Cancer Res. 13, 6257-6266 (2007).
73. Berns, K. et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428, 431-437 (2004).
74. INK4A-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol. Cell. Biol. 20, 1436-1447 (2000).
75. Snijders, P. J. F. et al. Telomerase activity exclusively in cervical carcinomas and a subset of cervical intraepithelial neoplasia grade III lesions: strong association with elevated messenger RNA levels of its catalytic subunit and high-risk human papillomavirus DNA. Cancer Res. 58, 3812-3818 (1998).
76. Hynes, N. E. & Lane, H. A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Rev. Cancer 5, 341-354 (2005).
77. Lin, S. Y . et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nature Cell Biol. 3, 802-808 (2001).
78. Lo, H. W. et al. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 7, 575-589 (2005).
79. Goessel, G. et al. Creating oral squamous cancer cells: a cellular model of oral-esophageal carcinogenesis. Proc. Natl Acad. Sci. USA 102, 15599-15604 (2005).
80. Ozanne, B., Richards, C. S., Hendler, F., Burns, D. & Gusterson, B. Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas. J. Pathol. 149, 9-14 (1986).
81. Grandis, J. R. & Tweardy, D. J. Elevated levels of transforming growth factor α and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 53, 3579-3584 (1993).
82. Hama, T. et al. Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma. Oncologist 14, 900-908 (2009).
83. Bonner, J. A. et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354, 567-578 (2006).
84. Morandell, S. et al. Phosphoproteomics strategies for the functional analysis of signal transduction. Proteomics 6, 4047-4056 (2006).
85. Lee, J. W. et al. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin. Cancer Res. 11, 2879-2882 (2005).
86. Loeffler-Ragg, J. et al. Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur. J. Cancer 42, 109-111 (2006).
87. Ekstrand, A. J., Sugawa, N., James, C. D. & Collins, V. P. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N-and/or C-terminal tails. Proc. Natl Acad. Sci. USA 89, 4309-4313 (1992).
88. Sok, J. C. et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin. Cancer Res. 12, 5064-5073 (2006).
89. Ishitoya, J. et al. Gene amplification and overexpression of EGF receptor in squamous cell carcinomas of the head and neck. Brit. J. Cancer 59, 559-562 (1989).
90. Temam, S. et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J. Clin. Oncol. 25, 2164-2170 (2007).
91. Sheu, J. J. C. et al. Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. Cancer Res. 69, 2568-2576 (2009).
92. Knudsen, B. S. & Vande Woude, G. Showering c-MET-dependent cancers with drugs. Curr. Opin. Genet. Dev. 18, 87-96 (2008).
93. Seiwert, T. Y. et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 69, 3021-3031 (2009).
94. Knowles, L. M. et al. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin. Cancer Res. 15, 3740-3750 (2009).
95. Wang, D. et al. Mutation and downregulation of the transforming growth factor beta type II receptor gene in primary squamous cell carcinomas of the head and neck. Carcinogenesis 18, 2285-2290 (1997).
96. Huntley, S. P . et al. Attenuated type II TGF-B receptor signalling in human malignant oral keratinocytes induces a less differentiated and more aggressive phenotype that is associated with metastatic dissemination. Int. J. Cancer 110, 170-176 (2004).
97. Qiu, W., Schonleben, F., Li, X. & Su, G. H. Disruption of transforming growth factor β-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4. Cancer Lett. 245, 163-170 (2007).
98. Bornstein, S. et al. Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation. J. Clin. Invest. 11 9, 3408-3419 (2009).
99. Mishra, A., Bharti, A. C., Varghese, P., Saluja, D. & Das, B. C. Differential expression and activation of NF-κB family proteins during oral carcinogenesis: role of high risk human papillomavirus infection. Int. J. Cancer 11 9, 2840-2850 (2006).
100. Karin, M. Nuclear factor-κB in cancer development and progression. Nature 441, 431-436 (2006).
101. Perkins, N. D. Integrating cell-signalling pathways with NF-κB and IKK function. Nature Rev. Mol. Cell Biol. 8, 49-62 (2007).
102. Cohen, J. et al. Attenuated transforming growth factor β signaling promotes nuclear factor-κB activation in head and neck cancer. Cancer Res. 69, 3415-3424 (2009).
103. Engelman, J. A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nature Rev. Cancer 9, 550-562 (2009).
104. Kozaki, K. et al. PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma. Cancer Sci. 97, 1351-1358 (2006).
105. Qiu, W. L. et al. PIK3CA mutations in head and neck squamous cell carcinoma. Clin. Cancer Res. 12, 1441-1446 (2006).
106. Murugan, A. K., Hong, N. T., Fukui, Y., Munirajan, A. K. & Tsuchida, N. Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas. Int. J. Oncol. 32, 101-111 (2008).
107. Okami, K. et al. Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Res. 58, 509-511 (1998).
108. Redon, R. et al. A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains. Cancer Res. 61, 4122-4129 (2001).
109. Woenckhaus, J. et al. Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma. J. Pathol. 198, 335-342 (2002).
110. Pantel, K. & Brakenhoff, R. H. Dissecting the metastatic cascade. Nature Rev. Cancer 4, 448-456 (2004).
111. Rosenthal, E. L. & Matrisian, L. M. Matrix metalloproteases in head and neck cancer. Head Neck 28, 639-648 (2006).
112. Sun, P. C. et al. Transcript map of the 8p23 putative tumor suppressor region. Genomics 75, 17-25 (2001).
113. Scholnick, S. B. et al. Chromosome 8 allelic loss and the outcome of patients with squamous cell carcinoma of the supraglottic larynx. J. Natl Cancer Inst. 88, 1676-1682 (1996).
114. Sunwoo, J. B. et al. Localization of a putative tumor suppressor gene in the sub-telomeric region of chromosome 8p. Oncogene 18, 2651-2655 (1999).
115. Kraus, D. M. et al. CSMD1 is a novel multiple domain complement- regulatory protein highly expressed in the central nervous system and epithelial tissues. J. Immunol. 176, 4419-4430 (2006).
116. Roepman, P. et al. An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nature Genet. 37, 182-186 (2005).
117. Thiery, J. P. Epithelial-mesenchymal transitions in tumour progression. Nature Rev. Cancer 2, 442-454 (2002).
118. Ikushima, H. & Miyazono, K. TGFβ signalling: a complex web in cancer progression. Nature Rev. Cancer 10, 415-424 (2010).
119. Folkman, J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29, 15-18 (2002).
120. Kerbel, R. S. Tumor angiogenesis. N. Engl. J. Med. 358, 2039-2049 (2008).
121. Kyzas, P. A., Cunha, I. W. & Ioannidis, J. P. A. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin. Cancer Res. 11, 1434-1440 (2005).
122. Fei, J. et al. Prognostic significance of vascular endothelial growth factor in squamous cell carcinomas of the tonsil in relation to human papillomavirus status and epidermal growth factor receptor. Ann. Surg. Oncol. 16, 2908-2917 (2009).
123. Virgilio, L. et al. FHIT gene alterations in head and neck squamous cell carcinomas. Proc. Natl Acad. Sci. USA 93, 9770-9775 (1996).
124. Hibi, K. et al. AIS is an oncogene amplified in squamous cell carcinoma. Proc. Natl Acad. Sci. USA 97, 5462-5467 (2000).
125. Rocco, J. W., Leong, C. O., Kuperwasser, N., DeYoung, M. P. & Ellisen, L. W. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 9, 45-56 (2006).
126. Rodrigo, J. P., Lazo, P. S., Ramos, S., Alvarez, I. & Suarez, C. MYC amplification in squamous cell carcinomas of the head and neck. Arch. Otolaryngol. Head Neck Surg. 122, 504-507 (1996). (Pubitemid 26153860)
127. Carvalho, A. L. et al. Deleted in colorectal cancer is a putative conditional tumor-suppressor gene inactivated by promoter hypermethylation in head and neck squamous cell carcinoma. Cancer Res. 66, 9401-9407 (2006).
128. Avissar, M., Christensen, B. C., Kelsey, K. T. & Marsit, C. J. MicroRNA expression ratio is predictive of head and neck squamous cell carcinoma. Clin. Cancer Res. 15, 2850-2855 (2009).
129. Childs, G. et al. Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am. J. Pathol. 174, 736-745 (2009).
130. Cervigne, N. K. et al. Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma. Hum. Mol. Genet. 18, 4818-4829 (2009).
131. Kies, M. S. et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J. Clin. Oncol. 28, 8-14 (2010).
132. Almadori, G. et al. Multistep laryngeal carcinogenesis helps our understanding of the field cancerisation phenomenon: a review. Eur. J. Cancer 40, 2383-2388 (2004).
133. Poh, C. F. et al. Fluorescence visualization detection of field alterations in tumor margins of oral cancer patients. Clin. Cancer Res. 12, 6716-6722 (2006).
134. Roblyer, D. et al. Objective detection and delineation of oral neoplasia using autofluorescence imaging. Cancer Prev. Res. 2, 423-431 (2009).
135. Braakhuis, B. J. M. et al. Second primary tumors and field cancerization in oral and oropharyngeal cancer: molecular techniques provide new insights and definitions. Head Neck 24, 198-206 (2002).
136. Graveland, A. P. et al. Loss of heterozygosity at 9p and p53 immunopositivity in surgical margins predict local relapse in head and neck squamous cell carcinoma. Int. J. Cancer (in the press).
137. Derynck, R., Akhurst, R. J. & Balmain, A. TGF-β signaling in tumor suppression and cancer progression. Nature Genet. 29, 117-129 (2001).
138. Chaturvedi, A. K., Engels, E. A., Anderson, W. F. & Gillison, M. L. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J. Clin. Oncol. 26, 612-619 (2008).
139. Nasman, A. et al. Incidence of human papilloma virus positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int. J. Cancer 125, 362-366 (2009).
140. Jung, A. C. et al. Biological and clinical relevance of transcriptionally active human papillomavirus (HPV) infection in oropharynx squamous cell carcinoma. Int. J. Cancer 126, 1882-1894 (2010).
141. Herrero, R. et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J. Natl Cancer Inst. 95, 1772-1783 (2003).
142. Hafkamp, H. C. et al. Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas. Int. J. Cancer 122, 2656-2664 (2008).
143. Hogg, R. P . et al. Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma. Eur. J. Cancer 38, 1585-1592 (2002).
144. Veeriah, S. et al. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc. Natl Acad. Sci. USA 106, 9435-9440 (2009).
145. Somers, K. D. et al. Frequent p53 mutations in head and neck cancer. Cancer Res. 52, 5997-6000 (1992).
146. Brennan, J. A. et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 332, 429-435 (1995).
147. Katoh, M. & Katoh, M. Identification and characterization of human TIPARP gene within the CCNL amplicon at human chromosome 3q25.31. Int. J. Oncol. 23, 541-547 (2003).
148. Sarkaria, I. et al. Squamous cell carcinoma related oncogene/DCUN1D1 is highly conserved and activated by amplification in squamous cell carcinomas. Cancer Res. 66, 9437-9444 (2006).
149. Bockmuhl, U. et al. Patterns of chromosomal alterations in metastasizing and nonmetastasizing primary head and neck carcinomas. Cancer Res. 57, 5213-5216 (1997).
150. Agochiya, M. et al. Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells. Oncogene 18, 5646-5653 (1999).
151. Inaba, T. et al. Genomic organization, chromosomal localization, and independent expression of human cyclin D genes. Genomics 13, 565-574 (1992).
152. Schuuring, E., Verhoeven, E., Mooi, W. J. & Michalides, R. J. Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas. Oncogene 7, 355-361 (1992).
153. Snijders, A. M. et al. Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma. Oncogene 24, 4232-4242 (2005).
154. Beder, L. B. et al. Genome-wide analyses on loss of heterozygosity in head and neck squamous cell carcinomas. Lab. Invest. 83, 99-105 (2003).